Abstract
This study was designed to investigate the effect of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1), a guanylate cyclase activator, upon the proliferation of rat mesangial cells and its underlying mechanism. YC-1 inhibited cell proliferation and DNA synthesis in a dose- and time-dependent manner. Flow cytometry cell-cycle studies revealed that YC-1 prevented the entry of cells from G1 into S phase. The expression of cyclin D1 and the kinase activity of cyclin D1/cyclin-dependent kinase (CDK)4 were lower within YC-1-treated cells, revealed by Western blotting, Northern blotting and kinase assays. YC-1 did not increase the intracellular cGMP concentration in mesangial cells. Inhibitors of soluble guanylate cyclase, protein kinase G, or protein kinase A also did not reverse the inhibitory effect elicited by YC-1, while co-treatment with p38 mitogen-activated protein kinase (MAPK) inhibitor could partially reverse the suppressive effect. YC-1 inhibited proliferation of mesangial cells and induced cell-cycle arrest by the reduction of cyclin D1 synthesis and cyclin D1/CDK4 kinase activity. This effect acts partially through p38 MAPK signal transduction activation and is independent of cGMP-signaling pathways.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Blotting, Northern
-
Blotting, Western
-
Bromodeoxyuridine / metabolism
-
CDC2-CDC28 Kinases / metabolism
-
Cell Cycle Proteins / metabolism
-
Cell Proliferation / drug effects*
-
Cells, Cultured
-
Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
-
Cyclic AMP-Dependent Protein Kinases / metabolism
-
Cyclic GMP / metabolism*
-
Cyclin D1 / genetics
-
Cyclin D1 / metabolism*
-
Cyclin E / metabolism
-
Cyclin-Dependent Kinase 2
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclin-Dependent Kinase Inhibitor p27
-
Cyclin-Dependent Kinases / metabolism
-
Enzyme Inhibitors / pharmacology
-
G1 Phase / drug effects
-
Gene Expression / drug effects
-
Glomerular Mesangium / cytology
-
Glomerular Mesangium / drug effects
-
Glomerular Mesangium / metabolism
-
Glycogen Synthase Kinase 3 / metabolism
-
Glycogen Synthase Kinase 3 beta
-
Guanylate Cyclase / antagonists & inhibitors
-
Guanylate Cyclase / metabolism
-
Imidazoles / pharmacology
-
Indazoles / pharmacology*
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Mitogen-Activated Protein Kinase 3 / metabolism
-
Phosphatidylinositol 3-Kinases / metabolism
-
Protein Kinase C / antagonists & inhibitors
-
Protein Kinase C / metabolism
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-akt
-
Pyridines / pharmacology
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Rats
-
Signal Transduction / drug effects*
-
Solubility
-
Tumor Suppressor Proteins / metabolism
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases / metabolism
Substances
-
Cdkn1a protein, rat
-
Cdkn1b protein, rat
-
Cell Cycle Proteins
-
Cyclin E
-
Cyclin-Dependent Kinase Inhibitor p21
-
Enzyme Inhibitors
-
Imidazoles
-
Indazoles
-
Proto-Oncogene Proteins
-
Pyridines
-
RNA, Messenger
-
Tumor Suppressor Proteins
-
Cyclin D1
-
Cyclin-Dependent Kinase Inhibitor p27
-
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
-
Glycogen Synthase Kinase 3 beta
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt
-
Cyclic AMP-Dependent Protein Kinases
-
Protein Kinase C
-
CDC2-CDC28 Kinases
-
Cdk2 protein, rat
-
Cdk4 protein, rat
-
Cyclin-Dependent Kinase 2
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinases
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
p38 Mitogen-Activated Protein Kinases
-
Glycogen Synthase Kinase 3
-
Guanylate Cyclase
-
Bromodeoxyuridine
-
Cyclic GMP
-
SB 203580